Concepedia

E Kerukadho

EK

5

Publications

189

Citations

5

H-Index

2016

Active since

Affiliations

Infectious Diseases Institute(Current)

University College London

Dignitas International

University of Malawi

National University of Singapore

E Kerukadho is an author at Infectious Diseases Institute specializing in malaria, immunodeficiencies, and aids pathogenesis.

Top concepts

Publications per year

2016–2018

5

Publications

5

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

Nicholas I. Paton, Cissy Kityo, Immaculate Nankya et al. · The Lancet HIV · 2017 · 79 citations · Full text

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

James Hakim, Cissy Kityo, Anne Hoppé et al. · The Lancet Infectious Diseases · 2017 · 41 citations · Full text

Virological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in Northwestern Uganda

Jonathan Izudi, Sunday Alioni, E Kerukadho et al. · BMC Infectious Diseases · 2016 · 29 citations · Full text

Hookworm infection is associated with decreased CD4+ T cell counts in HIV-infected adult Ugandans

Bożena M Morawski, Yunus Miya, E Kerukadho et al. · PLoS neglected tropical diseases · 2017 · 29 citations · Full text

, , +24

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

Cissy Kityo, David Dunn, Anne Hoppé et al. · Clinical Infectious Diseases · 2018 · 11 citations · Full text

Rows per page

1–5 of 5